Personalis, Inc. (PSNL)

In the past six months, Personalis, Inc. stock has experienced significant movements, with a substantial increase of 135.60% over the last six months and a 196.95% increase over the last year. The stock reached a 52-week high of $11.40 on November 26, 2025, but dropped by 4.4% to $10.72 on November 27, 2025. Key financial events include Q1, Q2, and Q3 2025 earnings releases, the Annual General Meeting held on May 16, 2025, and a revenue outlook adjustment on November 4, 2025. Several firms have reiterated or raised their price targets and ratings in November 2025, with a consensus of "Moderate Buy" from analysts. On November 3, 2025, CEO Christopher M. Hall sold 29,612 shares of Personalis stock.

There is no explicit information indicating significant demand seasonality for Personalis, Inc.'s products and services. The company has noted that adjustments to its revenue outlook do not reflect a change in underlying demand for its technology but rather the "lumpy and unpredictable nature of our legacy translational research business."

Personalis, Inc. is a genomics company specializing in advanced genomic sequencing and analytics solutions for personalized cancer therapies, operating within the Healthcare sector, specifically in the Biotechnology & Medical Research industry. The company develops and commercializes next-generation sequencing (NGS)-based cancer genomic tests and services, including the ImmunoID NeXT Platform, NeXT Personal, NeXT Personal Dx, NeXT Dx Test, and other Pharma Research Solutions. They also offer sequencing and data analysis services.

Personalis, Inc. is headquartered in Fremont, California, USA, and maintains an operational presence in both the United States and the United Kingdom. Its employees are located across five continents, including North America, Asia, and Europe.

Personalis has maintained a generally positive brand reputation, particularly within the precision oncology and genomics fields. This is due to strategic collaborations, capital investment, industry presence, innovative focus, and analyst sentiment. However, the company's persistent unprofitability and mounting losses, along with adjustments to revenue outlook due to "lumpy and unpredictable" business, could be areas of concern that might impact reputation if not effectively managed.

Personalis, Inc. has a diverse ownership structure. Institutional investors hold approximately 42% to 58.82% of the company's stock, with major institutional owners including Merck & Co., Inc., Lightspeed Management Company, L.L.C., ARK Investment Management LLC, BlackRock, Inc., Vanguard Group Inc, and T. Rowe Price Investment Management, Inc. Insiders own approximately 7.38% to 40.66% of the stock, while the general public holds around 17% to 33.80%. Public companies also hold a notable stake, around 30%.